Clinical trial

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

NCT05757843

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2024-09-13

PhasePHASE2

Study timeline

Study start (estimated)2024-09-13Date precision: day

Registry last updated2024-09-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLC, Stage IIIunresolved

Interventions

Signatera ctDNA testDIAGNOSTIC_TEST

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

Indiana Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05757843 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.